Higher baseline frequencies of CD8+ PD‐1+ TIGIT+ T cells were associated with shorter mPFS (estimated 1.0 vs. 4.0 months) and mOS (estimated 4.0 vs. not reached at 12 months) in advanced NSCLC patients (n = 263) receiving αPD‐(L)1 therapies (Figure 3A).57 Here, CD8A is linked to non-small cell lung carcinoma.